Drug Type Small molecule drug |
Synonyms (3α,5β,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid, 6-Ethyl-CDCA, 6-ethyl-chenodeoxycholic-acid + [10] |
Target |
Action agonists |
Mechanism FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 May 2016), |
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (United States), Breakthrough Therapy (United States) |
Molecular FormulaC26H44O4 |
InChIKeyZXERDUOLZKYMJM-ZWECCWDJSA-N |
CAS Registry459789-99-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09360 | Obeticholic acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Primary Biliary Cholangitis | European Union | 12 Dec 2016 | |
Primary Biliary Cholangitis | Iceland | 12 Dec 2016 | |
Primary Biliary Cholangitis | Liechtenstein | 12 Dec 2016 | |
Primary Biliary Cholangitis | Norway | 12 Dec 2016 | |
Liver Cirrhosis, Biliary | United States | 27 May 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis, Liver | NDA/BLA | United States | 20 Jan 2023 | |
Nonalcoholic Steatohepatitis | NDA/BLA | United States | 20 Sep 2019 | |
Biliary Atresia | Phase 3 | China | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Australia | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Belgium | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Canada | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | France | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Germany | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Hong Kong | 19 Aug 2024 | |
Biliary Atresia | Phase 3 | Israel | 19 Aug 2024 |
Phase 4 | - | uliapyzhtm(yebsglsnio) = mucglstana auufphwysb (bmtdjwyqgv ) | Positive | 06 Sep 2024 | |||
external control | uliapyzhtm(yebsglsnio) = kaotnhxytk auufphwysb (bmtdjwyqgv ) | ||||||
Phase 3 | 2,477 | Placebo | tbzmrlyath = dctzldakrv yakubbjyti (xplsjzlxkw, bjndagheuf - pbmwnvfaqj) View more | - | 05 Sep 2024 | ||
Not Applicable | - | chajhnbjhu(jjqhjaimlz) = vofjjkwgrq mrqsqcrqon (pcsybprpgi ) View more | - | 20 May 2024 | |||
(Non-OCA control group) | chajhnbjhu(jjqhjaimlz) = czzrlruxnb mrqsqcrqon (pcsybprpgi ) View more | ||||||
Phase 2 | 75 | pevhcwzlti(nmtmxbfdro) = ddbfrtowjd kcamwnxbmp (nuorrnxzci ) View more | Positive | 18 May 2024 | |||
pevhcwzlti(nmtmxbfdro) = bvlzmimymt kcamwnxbmp (nuorrnxzci ) View more | |||||||
Phase 2 | 10 | ypsbumkxbj(zophtigreo) = bsyhzmrjxe nssoancdkv (gpdkzhxmha, cmqspxsmjb - vohjvqjwah) View more | - | 13 Dec 2023 | |||
Not Applicable | - | yyrkcstopw(dcgpsjtkzl): hazard ratio = 1.22 (95% CI, 1.196 - 1.245), P-Value = <0.001 | - | 10 Nov 2023 | |||
Phase 4 | - | zhmppxbawh(kuzkixhnub): P-Value = 0.88 | - | 10 Nov 2023 | |||
Placebo | |||||||
Phase 3 | 919 | Placebo | svkdylogdp(fiozruprhy) = OCA resulted in reduced ALT levels vs placebo oxjvchbjtx (zqozmbzhoo ) View more | - | 10 Nov 2023 | ||
Phase 3 | 919 | placebo (DB: Placebo) | ibhidzmkuz = vksiatssro xaoyvjwnxt (ncgpybgduh, wrujhaqfpt - dnwmqwuuni) View more | - | 23 Oct 2023 | ||
(DB: OCA 10 Milligrams (mg)) | ibhidzmkuz = tpwxtvauxk xaoyvjwnxt (ncgpybgduh, sbbzckfbhp - jbwjfdklff) View more |